First-Strike Rapid Predictive Dosimetry and Dose Response for 177 Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
Journal of Nuclear Medicine Technology · 2024-09 · 52 (3) · 212-218
DOI: 10.2967/jnmt.123.267067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine Technology, online erschienen am 20.06.2024. Verfasst von Yung Hsiang Kao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia; yung.kao@mh.org.au. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Radiometry, Lutetium, Neoplasm Metastasis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
We devised and clinically validated a schema of rapid personalized predictive dosimetry for 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. It supersedes traditional empiric prescription by providing clinically meaningful predicted absorbed doses for first-strike optimization.
Methods
Prostate-specific membrane antigen PET was conceptualized as a simulation study that captures the complex dosimetric interplay between tumor, marrow, and kidneys at a single time point. Radiation principles of fractionation, heterogeneity, normal-organ constraints (marrow, kidney), absorbed dose, and dose rate were introduced. We created a predictive calculator in the form of a free, open-source, and user-friendly spreadsheet that can be completed within minutes. Our schema achieves speed and accuracy by sampling tissue radioconcentrations (kBq/cm3) to be analyzed in conjunction with clinical input from the user that reflect dosimetric preconditions. The marrow-absorbed dose constraint was 0.217 Gy (dose rate, ≤0.0147 Gy/h) per fraction with an interfraction interval of at least 6 wk.
Results
Our first 10 patients were analyzed. The first-strike mean tumor-absorbed dose threshold for any prostate-specific antigen (PSA) response was more than 10 Gy (dose rate, >0.1 Gy/h). The metastasis with the lowest first-strike tumor-absorbed dose correlated the best with the percentage decrease of PSA; its threshold to achieve hypothetical zero PSA was 20 Gy or more. Each patient's PSA doubling time can be used to personalize their unique absorbed dose-response threshold. The predicted mean first-strike prescription constrained by marrow-absorbed dose rate per fraction was 11.0 ± 4.0 GBq. Highly favorable conditions (tumor sink effect) were dosimetrically expressed as the combination of tumor-to-normal-organ ratios of more than 150 for marrow and more than 4 for kidney. Our schema obviates the traditional role of the SUV as a predictive parameter.
Conclusion
Our rapid schema is feasible to implement in any busy real-world theranostics unit and exceeds today's best practice standards. Our dosimetric thresholds and predictive parameters can radiobiologically rationalize each patient's first-strike prescription down to a single becquerel. Favorable tumor-to-normal-organ ratios can be prospectively exploited by predictive dosimetry to optimize the first-strike prescription. The scientific framework of our schema may be applied to other systemic radionuclide therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia; yung.kao@mh.org.au.
- GenesisCare Theranostics, North Shore Health Hub, Sydney, New South Wales, Australia.
- Medical Imaging Department, Cabrini Hospital, Malvern, Victoria, Australia; and.
- Department of Nuclear Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia.
- GenesisCare Theranostics, Cabrini Hospital, Malvern, Victoria, Australia.
Zitieren
APA
Kao, Y. H., Falzone, N., Pearson, M., & Sivaratnam, D. (2024). First-Strike Rapid Predictive Dosimetry and Dose Response for 177 Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine Technology, 52(3), 212-218. https://doi.org/10.2967/jnmt.123.267067
Vancouver
Kao YH, Falzone N, Pearson M, Sivaratnam D. First-Strike Rapid Predictive Dosimetry and Dose Response for 177 Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine Technology. 2024;52(3):212-218. doi:10.2967/jnmt.123.267067
BibTeX
@article{Kao2024,
author = {Kao, Yung Hsiang and Falzone, Nadia and Pearson, Michael and Sivaratnam, Dinesh},
title = {First-Strike Rapid Predictive Dosimetry and Dose Response for 177 Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer},
journal = {Journal of Nuclear Medicine Technology},
year = {2024},
volume = {52},
number = {3},
pages = {212--218},
doi = {10.2967/jnmt.123.267067}
}
EUVIMED